Phendimetrazine
From Wikipedia, the free encyclopedia
 |
|
|
Phendimetrazine
|
|
| Systematic (IUPAC) name | |
| 3,4-Dimethyl-2-phenyl-morpholine | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C12H17NO |
| Mol. mass | 191.27 |
| Pharmacokinetic data | |
| Bioavailability | Peak plasma levels occur within 1 to 3 hours. Absorption is usually complete by 4 to 6 hours |
| Metabolism | hepatic |
| Half life | 19-24 hours |
| Excretion | Urinary elimination |
| Therapeutic considerations | |
| Pregnancy cat. |
C (US) |
| Legal status |
C-III (US) |
| Routes | Oral |
| Indicated for: |
Phendimetrazine (Bontril®) is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances. In the United States, phendimetrazine is a Schedule III controlled substance under the Uniform Controlled Substances Act of 1970.
Phendimetrazine is used clinically in the form of phendimetrazine tartrate.
Approximately 30% of a given dose of phendimetrazine is metabolized into phenmetrazine, which may account for part of its anorectic effect, and probably also influences abuse potential; individuals who metabolise a greater proportion of phendimetrazine into phenmetrazine are more likely to develop problems with dependence and addiction.
[edit] External links
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
According to the "List of psychotropic substances under international control," phendimetrazine is a Schedule IV controlled substance.
